GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magle Chemoswed Holding AB (OSTO:MAGLE) » Definitions » Debt-to-EBITDA

Magle Chemoswed Holding AB (OSTO:MAGLE) Debt-to-EBITDA : 2.55 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Magle Chemoswed Holding AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Magle Chemoswed Holding AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr30.0 Mil. Magle Chemoswed Holding AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr41.9 Mil. Magle Chemoswed Holding AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr28.2 Mil. Magle Chemoswed Holding AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 2.55.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Magle Chemoswed Holding AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:MAGLE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.4   Med: 1.94   Max: 3.01
Current: 2.3

During the past 6 years, the highest Debt-to-EBITDA Ratio of Magle Chemoswed Holding AB was 3.01. The lowest was 0.40. And the median was 1.94.

OSTO:MAGLE's Debt-to-EBITDA is ranked worse than
57.71% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs OSTO:MAGLE: 2.30

Magle Chemoswed Holding AB Debt-to-EBITDA Historical Data

The historical data trend for Magle Chemoswed Holding AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magle Chemoswed Holding AB Debt-to-EBITDA Chart

Magle Chemoswed Holding AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 1.30 3.01 2.01 1.95 1.92

Magle Chemoswed Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.99 1.36 2.95 1.57 2.55

Competitive Comparison of Magle Chemoswed Holding AB's Debt-to-EBITDA

For the Biotechnology subindustry, Magle Chemoswed Holding AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magle Chemoswed Holding AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magle Chemoswed Holding AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Magle Chemoswed Holding AB's Debt-to-EBITDA falls into.



Magle Chemoswed Holding AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Magle Chemoswed Holding AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(23.062 + 37.24) / 31.404
=1.92

Magle Chemoswed Holding AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(30.014 + 41.877) / 28.164
=2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Magle Chemoswed Holding AB  (OSTO:MAGLE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Magle Chemoswed Holding AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Magle Chemoswed Holding AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Magle Chemoswed Holding AB (OSTO:MAGLE) Business Description

Traded in Other Exchanges
N/A
Address
Agneslundsvagen 27, Malmo, SWE, 21215
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.

Magle Chemoswed Holding AB (OSTO:MAGLE) Headlines

No Headlines